Chinese medicine enterprises accelerate the layout transformation of bio-innovative pharmaceutical investment focus

With the change of policy, Chinese medicine enterprises have increased their investment and layout in the field of biopharmaceuticals. According to the Securities Daily reporter combed, including Jiuzhitang, Step Pharmaceuticals, Yunnan White Medicine, Tianshili and other large-scale Chinese medicine enterprises are in the layout of bio-innovative medicine field.
" is like the rapid development of the mobile Internet, the development direction of the pharmaceutical industry is biomedicine. "A Chinese medicine company, Dong Shi, in an interview with securities daily, said.
An industry observer told securities daily reporter: "Chinese medicine enterprises in recent days is not too good, so generally choose to turn in several directions: First, to the big health category, such as health care products, daily transformation; In ,
stem cells have become one of the important directions in the field of life science, which has attracted wide worldwide attention, and the stem cell therapy technology and industry have developed rapidly. China has also issued a number of policy support, such as the 2017 National Development and Reform Commission issued the "Strategic Emerging Industries Key Products and Services Guidance Directory" to support the development of bio-industry in areas such as cell therapy products, including stem cells;
it is worth mentioning that most domestic enterprises stay in stem cell storage and the provision of medical beauty services, stem cells for the treatment of human diseases is still in the clinical research stage. Since this year, including Jiuzhitang, Tianshili and other listed companies layout stem cell therapy field.
, it is understood that jiuzhitang initiated the establishment of the Yanhe Sailing Fund invested in the United States Systemica Cell Technology Co., Ltd. At the same time, the establishment of JiuzhiTang Meike (Beijing) Cell Technology Co., Ltd., as the United States Systemica stem cell technology in China's only undertaker. At present, Jiuzhitang Meike is building an allogeneic stem cell production site in Daxing District of Beijing that meets the CGMP standards of the United States and the European Union, and will be used for human bone marrow-filled stem cells and neural stem cell production. In addition, Jiuzhitang (U.S.A.) will cooperate with top hospitals in China to conduct multi-center clinical trials, and plans to conduct stem cell clinical research on nervous system, cardiovascular and cerebrovascular diseases on the basis of the good clinical trial results of Systemica Corporation in the United States, and ultimately promote the early domestic market of stem cell drugs.
" innovation drives enterprise development, the value of traditional Chinese medicine needs to be tapped. In the process of development, Jiuzhitang must inject innovative factors. Li Zhenguo, chairman of Jiuzhitang, told reporters that with the promotion of policies, the stem cell industry will usher in a new period of development.
year, another listed company involved in the stem cell industry has been Tian Shili. In July, Tiansli announced that it had signed an investment agreement with mesoblast Limited, a stem cell research and development company, and a commercialization agreement for product development, in which it subscribed for $20 million of its common stock and introduced two of its Stem cell products (MPC-150-IM) in FDA Clinical Phase III and Phase II trials for the treatment of congealative heart failure, and MPC-25-IC, for the treatment of acute myocardial infarction. Under the agreement, Tiansli will receive exclusive development, production and commercialization interests in cooperative stem cell products in China (including Hong Kong and Macau).
in the industry, through cooperation with foreign research and development enterprises, help domestic enterprises to foreign advanced technology and research and development strength grafted to the domestic, to achieve corner oversized.Biopharmaceuticals into an investment hot spot
it is worth mentioning that in the Chinese medicine industry, in addition to Jiuzhitang, Tianshili, including step pharmaceutical and other listed companies are also in the field of biopharmaceutical layout and transformation.
Pharmaceuticals issued the Biopharmaceutical Strategic Regulations to the outside world. Step Pharma said that the company will make every effort to build a biopharmaceutical industry chain, through the construction of a platform, talent, search for cooperation model, and constantly enhance the strength of biopharmaceutical research and development. Earlier, in an interview with Securities Daily, Step Pharmaceutical Chairman Zhao Tao said: "The outside world has been regarded as a Chinese pharmaceutical enterprises, but step pharmaceutical five years ago began to transform, increased investment in chemical drugs, bio-innovative drugs, the current transformation is relatively smooth."
the transformation of the pharmaceutical industry from a modern Chinese medicine enterprise to a chemical innovation drug, adopting a model of cooperation with domestic CRO giants, introducing 10 innovative compound entities from Pharmaceutical Mingkangde, and moving directly beyond the long and uncertain stage of compound screening to the clinical level.
Yunnan White Pharmaceuticals said in an investor exchange report released on September 14th that there are two lines in the company's initial direction for deep-ploughed drugs, one of which is to look for cutting-edge biotech products to cut directly into the high end.
The above-mentioned industry observers told reporters that these listed companies have a relatively high starting point, behind enough strength to support the company in the field of biotechnology exploration, but whether it can be successful also depends on the specific trading team, research and development strategy, specific products. (Securities Daily)